3rd Quarter - Report
ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
ACA Implementation Issues 21st Century Cures Initiative (Chairman Upton) Biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Taxation/Internal Revenue Code TAX
Tax Reform Act of 2014 (Chairman Camp Draft) Corporate Tax Reform proposals Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Copyright/Patent/Trademark CPT
Patent Reform: Schumer/Cornyn Compromise Draft Patent Transparency and Improvements Act, S. 1720 Patent Abuse Reduction Act, S. 1013
| Lobbyist | Covered position, as disclosed |
|---|---|
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.